[Form 4] SI-BONE, Inc. Insider Trading Activity

Rhea-AI Filing Summary

SI-BONE, Inc. (SIBN)11/17/2025, she sold several small blocks of common stock, including 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996.

The filing explains that these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as "sell to cover" transactions rather than discretionary trades. On 11/18/2025, 5,411 additional shares were sold at a weighted average price of $17.6978 under a Rule 10b5-1 trading plan dated December 13, 2024.

After these transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.

11/19/2025 - 07:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FRANCIS LAURA

(Last) (First) (Middle)

C/O SI-BONE, INC.

471 EL CAMINO REAL, SUITE 101

(Street)

SANTA CLARA CA 95050

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SI-BONE, Inc. [ SIBN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		2,028	D	$17.4401(2)	417,676	D
Common Stock	11/17/2025		S(1)		2,231	D	$17.4449(3)	415,445	D
Common Stock	11/17/2025		S(1)		3,197	D	$17.4341(4)	412,248	D
Common Stock	11/17/2025		S(1)		3,885	D	$17.3996(4)	408,363(5)	D
Common Stock	11/18/2025		S(6)		5,411	D	$17.6978(7)	351,319	I	by Trust(8)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

2. This transaction was executed in multiple trades at prices ranging from $17.31 USD to $17.56 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. This transaction was executed in multiple trades at prices ranging from $17.28 USD to $17.56 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. This transaction was executed in multiple trades at prices ranging from $17.295 USD to $17.57 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. Includes 373,980 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

6. The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated December 13th, 2024.

7. This transaction was executed in multiple trades at prices ranging from $17.46 USD to $17.91 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote

8. Shares held by The David & Laura Joint Rev Tr.

Remarks:

	/s/ Michael A. Pisetsky, Attorney-in-Fact for Laura A. Francis	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SI-BONE (SIBN) report in this Form 4?

The filing reports that Laura A. Francis, Chief Executive Officer and Director of SI-BONE, Inc., sold multiple small blocks of common stock on 11/17/2025 and 11/18/2025.

How many SI-BONE (SIBN) shares did Laura A. Francis sell and at what prices?

On 11/17/2025, Francis sold 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996. On 11/18/2025, she sold 5,411 shares at a weighted average price of $17.6978.

Why were some of the SI-BONE (SIBN) shares sold by Laura A. Francis?

The filing states that the sale on 11/17/2025 represents shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units, executed as a "sell to cover" transaction rather than a discretionary trade.

Were any of the SI-BONE (SIBN) insider sales made under a Rule 10b5-1 trading plan?

Yes. The sale reported on 11/18/2025 was effected pursuant to a Rule 10b5-1 trading plan dated December 13, 2024, which is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

How many SI-BONE (SIBN) shares does Laura A. Francis own after these transactions?

After the reported transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.

What do the weighted average prices in the SI-BONE (SIBN) Form 4 mean?

Each reported price is a weighted average sale price for multiple trades executed in a price range. For example, the $17.4401 price reflects trades between $17.31 and $17.56, and full trade details are available from the reporting person upon request.